Related Experiment Videos
Mild hypokalaemia is not a risk factor in treated hypertensives
Insights
Hypokalaemia (low serum potassium) did not increase mortality in treated hypertensive patients. Serum potassium levels were similar in deceased and surviving patients, regardless of treatment. This finding was confirmed by statistical analyses.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Hypokalaemia is a potential risk factor in hypertensive patients.
- Diuretic use is a common cause of hypokalaemia.
- The association between hypokalaemia and mortality in treated hypertension requires further investigation.
Purpose of the Study:
- To examine the relationship between hypokalaemia and mortality in treated hypertensive patients.
- To compare serum potassium levels in deceased and surviving patients.
- To determine if hypokalaemia predicts adverse outcomes in hypertension management.
Main Methods:
- Retrospective analysis of 3783 hypertensive patients followed for 6.5 years.
- Serum potassium levels were measured at the last clinic visit for 1907 patients.
- Age-adjusted mortality rates were calculated based on serum potassium quartiles and treatment groups.
Main Results:
- No significant difference in serum potassium was observed between deceased and surviving patients.
- Serum potassium levels showed no significant association with mortality in various treatment groups.
- Low serum potassium (less than 3.7 mmol/l) did not correlate with increased age-adjusted mortality rates.
Conclusions:
- Hypokalaemia does not appear to be a significant predictor of mortality in treated hypertensive patients.
- Treatment strategies for hypertension should consider other risk factors beyond serum potassium levels.
- Further research is needed to fully elucidate the complex interplay between electrolytes, medications, and cardiovascular outcomes.
Abstract:
The possibility that hypokalaemia might increase the mortality of treated hypertensives in the Glasgow Blood Pressure Clinic has been examined by comparison of serum potassium in decedents and survivors and by calculation of age-adjusted mortality rates for patients grouped in quartiles of serum potassium measured at the last clinic visit. In this study, 3783 patients with non-malignant hypertension were followed for an average of 6.5 years and of these 1907 had one or more measurements of serum potassium during their last year of attendance. Serum potassium fell in 414 patients given diuretics with or without other drugs except beta-blockers. This fall was similar in those who died of ischaemic heart disease (3.71 mmol/l) and in those who survived (3.72 mmol/l). Serum potassium rose in 167 patients who received beta-blockers with or without other drugs except diuretics and fell slightly among 1326 patients taking other combinations of drugs. There were no significant differences in serum potassium between decedents and survivors in either of these treatment groups. Age-adjusted mortality in deaths per 1000 patient-years in the lowest quartile of serum potassium (less than 3.7 mmol/l) was 28.1 for men and 15.0 for women. Higher serum potassium was associated with slightly, but not significantly, higher mortality in both sexes. There was no relation between serum potassium and mortality in patients with left ventricular hypertrophy, nor was there a relation when death due to ischaemic heart disease was considered separately. Failure of hypokalaemia to predict outcome was confirmed by univariate and multivariate analyses which included, in addition to potassium, assessment of cigarette smoking, initial blood urea and electrocardiographic findings.(ABSTRACT TRUNCATED AT 250 WORDS)